Crispr Therapeutics price target lowered to $50 from $55 at RBC Capital

RBC Capital lowered the firm’s price target on Crispr Therapeutics to $50 from $55 and keeps a Sector Perform rating on the shares after its “quiet” Q3 results. Al eyes remain on PDUFA date of December 8 for exa-cel in, with approval highly likely following a “benign” AdCom recommendation, the firm tells investors in a research note. On commercial uptake however, RBC “remains cautious” given that the drug is initially restricted to severe patients, infrastructure may not be in place, and that patients will lose fertility as oocyte/sperm cryopreservation is an out-of-pocket expense, the analyst added.